- Home
- SAND vs MLTX Comparison
SAND vs MLTX Comparison
Compare SAND & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- MLTX
- Stock Information
- Founded
- SAND 2007
- MLTX 2021
- Country
- SAND Canada
- MLTX Switzerland
- Employees
- SAND N/A
- MLTX N/A
- Industry
- SAND
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- SAND
- MLTX Health Care
- Exchange
- SAND NYSE
- MLTX Nasdaq
- Market Cap
- SAND 2.4B
- MLTX 2.3B
- IPO Year
- SAND N/A
- MLTX N/A
- Fundamental
- Price
- SAND $8.81
- MLTX $38.60
- Analyst Decision
- SAND Buy
- MLTX Strong Buy
- Analyst Count
- SAND 4
- MLTX 8
- Target Price
- SAND $9.13
- MLTX $80.50
- AVG Volume (30 Days)
- SAND 6.2M
- MLTX 423.9K
- Earning Date
- SAND 05-06-2025
- MLTX 05-20-2025
- Dividend Yield
- SAND 0.65%
- MLTX N/A
- EPS Growth
- SAND 32.83
- MLTX N/A
- EPS
- SAND 0.10
- MLTX N/A
- Revenue
- SAND $183,537,000.00
- MLTX N/A
- Revenue This Year
- SAND $16.62
- MLTX $103.42
- Revenue Next Year
- SAND $8.98
- MLTX N/A
- P/E Ratio
- SAND $90.20
- MLTX N/A
- Revenue Growth
- SAND 2.84
- MLTX N/A
- 52 Week Low
- SAND $4.92
- MLTX $31.42
- 52 Week High
- SAND $8.82
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- SAND 63.60
- MLTX 53.31
- Support Level
- SAND $8.32
- MLTX $36.75
- Resistance Level
- SAND $8.91
- MLTX $42.90
- Average True Range (ATR)
- SAND 0.29
- MLTX 2.06
- MACD
- SAND -0.03
- MLTX 0.03
- Stochastic Oscillator
- SAND 89.39
- MLTX 58.04
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.